fda import alert green list glp-1 semaglutide tirzepatide 2025 🚨Big shifts in the landscape🚨 - FDA launches "Green List" to

Biased GLP1 agonists would need to provide distinct benefits over semaglutide to warrant the investment required to bring a new agent to market

Many people find it easier to digest, and it mixes well without needing a lot of extra ingredients

MANAGEMENT OF OBESITY Older pharmacological options for chronic weight management, such as orlistat, phenterminetopiramate and naltrexonebupropion, typically show moderate efficacy (~3%9% mean weight loss over that achieved with lifestyle intervention alone)

military infrastructure

It is particularly beneficial for those who have a body mass index (BMI) of 30 or higher or a BMI of 27 or higher with obesity-related health conditions such as type 2 diabetes or hypertension

Some people taking semaglutide, tirzepatide and similar medications describe losing interest not only in food, but also in hobbies, relationships, socialising and everyday experiences they previously enjoyed